Trial of UB-VV111 with or without rapamycin for B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of lymphoma (large B-cell) or leukemia (CLL) that has returned or not responded to treatment
- You have measurable disease as determined by standard tests
- You are in good overall health (able to care for yourself and out of bed more than half the day)
- You have not had a prior bone marrow transplant from another person, gene therapy, or certain cell therapies (except CAR T cells or tumor-infiltrating lymphocytes)
- You do not have uncontrolled infections, active HIV, hepatitis B or C, or serious heart conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
This trial tests a new combination therapy (UB-VV400 plus rapamycin) for people with B-cell cancers that have come back or not responded to previous treatment. It aims to see if this approach is safe and effective.
This trial tests an investigational cell therapy called UB-VV500 combined with rapamycin, a drug that may help the therapy work better. It is for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination is safe and effective.
A trial testing an experimental drug (UBX-303061) for people with certain B-cell blood cancers (like CLL, DLBCL, or MCL) that have returned or not responded to at least two other treatments. The goal is to see if the drug is safe and works when other options are no longer available.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.